Patent · US Active

Compounds and methods for modulating activation of NF-κB

US8263326B2 · kind B2 · utility

0Cited by

23References

5Claims

0Family size

Assignee

Signal Pharmaceuticals, LLC · US

Inventors

Anthony Manning · Cambridge, US
Frank Mercurio · Rancho Santa Fe, US
Sharon Amit · Beer Sheva, IL
Yinon Ben-Neriah · Nesher, IL
Matti Davis · Shetulim, IL
Ada Hatzubai · Mevaseret Tsiyon, IL
Avraham Yaron · Jerusalem, IL
Irit Alkalay · Jerusalem, IL
Aaron Ciechanover · Haifa, IL

Key dates

Filing date	Aug 8, 2008
Grant date	Sep 11, 2012
Priority date	—
Expiry date	Aug 8, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ. Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.